# 肿瘤设备市场

> 肿瘤学设备市场研究报告按应用（放射治疗、化疗、外科肿瘤学、支持性护理、诊断成像）、按设备类型（放射治疗设备、化疗给药设备、外科仪器、诊断成像设备、支持性设备）、按最终用户（医院、门诊手术中心、专科肿瘤诊所、居家护理环境）、按技术（光动力疗法、放射治疗、冷冻消融、电化学疗法）以及按地区（北美、欧洲、南美、亚太、中东和非洲） - 预测到2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.18%
- **2024:** $ 78.82 Billion
- **2025:** $ 83.69 Billion
- **2035:** $ 152.48 Billion
- **Key Players:** Companies such as Medtronic(US), Boston Scientific (US), Abbott Laboratories (US), Siemens Healthineers (DE), Philips (NL), Bayer (DE), Varian Medical Systems (US), GE Healthcare (US), Stryker Corporation (US) are some of the major participants in the market.

**Report ID:** MRFR/Pharma/32277-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** June 25, 2026

**URL:** https://www.marketresearchfuture.com/reports/oncology-device-market-34121

---

## Market Summary

## **Global Oncology Device Market Overview**

As per MRFR analysis, the Oncology Device Market Size was estimated at 78.82 (USD Billion) in 2024. The Oncology Device Market Industry is expected to grow from 83.69 (USD Billion) in 2025 to 143.60 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 6.18% during the forecast period (2025 - 2034).

### **Key Oncology Device Market Trends Highlighted**

The Oncology Device Market is experiencing significant growth due to several key market drivers. An increase in cancer prevalence worldwide has heightened the demand for advanced diagnostic and treatment devices.

Furthermore, technological advancements are revolutionizing the sector, enabling the development of more precise and efficient devices. Increased funding for cancer research and rising awareness about early detection and treatment options also contribute to market expansion.

Healthcare reforms and initiatives aimed at improving cancer care are further fueling the adoption of innovative oncology devices, ensuring that patients receive the best possible solutions for their conditions.

Opportunities in the oncology device market are vast and varied. Companies have the chance to develop next-generation devices that integrate artificial intelligence and machine learning for improved diagnostic capabilities.

There is also a growing market for wearable technology that enables continuous monitoring of patients, providing real-time data to healthcare providers. Collaborations between technology firms and healthcare organizations could lead to breakthroughs in treatment devices.

Emerging markets present additional opportunities, as rising incomes and improved healthcare infrastructures pave the way for increased access to oncology treatments.

Companies that adapt their strategies to target these regions may find significant growth potential. Trends in recent times indicate a shift towards personalized medicine, with devices designed to cater to individual patient needs becoming more prevalent.

The integration of telemedicine in oncology care has also gained traction, enhancing patient access to specialized devices and consultations. Moreover, sustainability in device manufacturing is becoming a focal point, with companies exploring eco-friendly materials and practices.

Digital health solutions are on the rise and are expected to play a crucial role in the future of oncology care. These trends underscore an evolving landscape where innovative solutions and patient-centered approaches are becoming imperative for success in the Oncology Device Market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Oncology Device Market Drivers**

### **Rising Incidence of Cancer**

The Oncology Device Market is witnessing significant growth driven by the rising incidence of cancer across the globe. As cancer rates continue to escalate, there is an increasing demand for effective diagnostic and treatment technologies.

Governments and health organizations are prioritizing cancer prevention, diagnosis, and treatment, resulting in enhanced investment in healthcare infrastructure and technology. This global trend not only emphasizes the urgency of addressing cancer but also creates a robust market environment for oncology devices aimed at early detection and effective treatment.

Through technological innovations and advancements in medical devices, the market is poised to expand significantly, catering to the growing needs of an aging population and individuals predisposed to cancer due to lifestyle factors.

Moreover, public awareness about cancer symptoms and the benefits of early diagnosis is improving, leading to increased screening rates. All these factors collaboratively push the Oncology Device Market towards substantial growth, presenting numerous opportunities for manufacturers and healthcare providers to deliver improved clinical outcomes for patients around the world.

### **Technological Advancements in Oncology Devices**

Continuous technological advancements play a pivotal role in driving the Oncology Device Market. Innovations such as artificial intelligence, imaging technologies, and minimally invasive procedures are transforming the diagnostic and treatment landscape in oncology.

Enhanced imaging modalities enable healthcare professionals to precisely identify and target tumors, significantly improving treatment efficacy. Additionally, the integration of AI and machine learning algorithms in diagnostic procedures streamlines workflows, enabling faster and more accurate results.

As manufacturers invest in research and development to produce cutting-edge oncology devices, the market is increasingly filled with solutions that enhance patient care and outcomes, thereby propelling market growth.

### **Government Initiatives and Funding**

Government initiatives and increased funding for cancer research significantly influence the Oncology Device Market. Many governments are implementing programs aimed at boosting cancer treatment facilities, funding research projects, and increasing public access to innovative oncology devices.

These initiatives not only raise awareness around cancer prevention and therapy but also facilitate collaborations among stakeholders in the healthcare sector.

Enhanced funding for research initiatives encourages innovation in device development, ultimately leading to the availability of new and improved treatment options for patients. This supportive regulatory framework is expected to amplify market growth and development in the coming years.

## **Oncology Device Market Segment Insights**

### **Oncology Device Market Application Insights**

The Oncology Device Market revenue is extensively categorized into various applications, each playing a crucial role in the treatment and management of cancer.

Among the key applications, Radiation Therapy held a valued segment at 16.5 USD billion, expected to reach 28.5 USD billion by 2032. It remains one of the most dominant segments as it provides targeted radiation treatment necessary for the vast majority of cancer cases, making its importance paramount in the clinical setting.

Chemotherapy followed closely as a significant contributor, with a valuation of 25.0 USD billion in 2023 and projected to reach 41.0 USD billion by 2032. This application dominates due to the widespread use of pharmacological interventions in cancer treatment, offering systemic therapy that is vital for managing various cancer types.

Surgical Oncology was valued at 10.0 USD billion in 2023, representing a significant aspect of cancer treatment where surgical procedures are fundamental in removing tumors. Its projected growth to 17.0 USD billion by 2032 underscores its critical role, especially in early-stage cancers where surgical intervention can considerably improve patient outcomes.

The Supportive Care segment, with a value of 9.0 USD billion in 2023, shows a growth trajectory leading to 15.5 USD billion by 2032, reflecting the increasing recognition of the importance of palliative measures in enhancing the quality of life for cancer patients.

The Diagnostic Imaging segment also played a vital role, valued at 9.41 USD billion in 2023 and expected to grow to 17.0 USD billion by 2032, facilitating early detection and ongoing monitoring of cancer, which are essential for effective treatment planning.

These segments collectively represent a comprehensive overview of the Oncology Device Market statistics, showcasing how various applications contribute to the overall market growth. The integration of advanced technologies into these applications is driving efficiency and effectiveness in treatment protocols, thereby propelling the market forward.

However, challenges such as high treatment costs and access to specialized care remain significant barriers. Nonetheless, the continuous innovation and expanding research in oncology devices present various opportunities for market growth, aiming to enhance patient care and improve treatment outcomes in the ongoing battle against cancer.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Oncology Device Market Device Type Insights**

In terms of Device Type, this market is diverse and encompasses several key categories, including Radiotherapy Equipment, Chemotherapy Administration Devices, Surgical Instruments, Diagnostic Imaging Devices, and Supportive Devices.

Each of these areas plays a significant role in cancer treatment and patient management, with Radiotherapy Equipment, for instance, being crucial for delivering targeted treatment to patients, while Chemotherapy Administration Devices ensure safe and efficient drug delivery.

It is noteworthy that Surgical Instruments are essential for performing various oncological procedures, contributing to improved surgical outcomes, and Diagnostic Imaging Devices provide vital tools for early diagnosis and treatment planning, enhancing patient care.

Supportive Devices focus on patient comfort and quality of life during treatment, highlighting a holistic approach to cancer care. The expected growth of this market segment reflects not only advancements in technology and treatment methodologies but also the increasing prevalence of cancer worldwide, creating ample opportunities for innovation and enhancement within the Oncology Device Market.

### **Oncology Device Market End User Insights**

Hospitals are pivotal in providing comprehensive cancer care, leveraging advanced oncology devices to enhance treatment efficiency and patient outcomes.

A significant portion of the market is also contributed by Ambulatory Surgical Centers, which offer outpatient surgical services, making cancer treatments more accessible and streamlined. Specialized Oncology Clinics are essential as they focus exclusively on cancer care, utilizing cutting-edge devices to deliver tailored treatments.

Home Care Settings have gained prominence, particularly with the rise of telehealth and remote monitoring, enabling patients to receive care in their comfort zones.

Each of these end users significantly influences the Oncology Device Market revenue, highlighting their importance in the overall industry landscape. With the market expected to grow, understanding these end users' roles provides valuable insights into the trends, challenges, and opportunities that shape the Oncology Device Market today.

### **Oncology Device Market Technology Insights **

The expansion highlights the increasing demand for advanced cancer treatment options. Various technologies play a crucial role, including Photodynamic Therapy, Radiotherapy, Cryoablation, and Electrochemotherapy, which collectively cater to different cancer types and stages.

Photodynamic Therapy is becoming increasingly prevalent due to its ability to target cancer cells while minimizing damage to surrounding tissue, which enhances patient outcomes.

Radiotherapy continues to dominate the oncology device market, being a key treatment choice for a wide range of tumors and allowing for precise localization. Cryoablation is notable for its effectiveness in treating specific tumors by freezing cells, while Electrochemotherapy combines electrical pulses with [chemotherapy](../../../reports/chemotherapy-market-5791), significantly improving drug delivery into cancer cells.

The growth drivers for this segment include advances in technology, rising cancer incidences, and the rising demand for minimally invasive procedures. However, challenges such as high costs and regulatory hurdles may hinder market progress.

These insights into Oncology Device Market revenue and segmentation provide a deeper understanding of the dynamics in this growing industry, highlighting the opportunities present in the evolving landscape.

### **Oncology Device Market Regional Insights**

North America dominated this space with a valuation of 30.0 USD billion in 2023 and is expected to reach 50.0 USD billion by 2032, reflecting a major influence in advancements and utilization of oncology devices. Europe followed with a significant share of 20.0 USD billion in 2023, anticipated to grow to 30.0 USD billion, indicating robust health infrastructure and regulatory support in oncology treatments.

The APAC region, valued at 12.0 USD billion, is projected to witness considerable growth to 25.0 USD billion, driven by increasing healthcare accessibility and rising cancer incidence. South America, although smaller with an initial value of 4.0 USD billion, is expected to double to 8.0 USD billion, illustrating growing investment in healthcare technologies.

Meanwhile, the MEA segment, holding a value of 3.91 USD billion, is projected to increase to 7.0 USD billion, reflecting emerging market potential in oncology devices.

The differentiation in growth rates across these regions is influenced by factors like healthcare investments, technology adoption, and population demographics, making these markets unique within the Oncology Device Market landscape.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Oncology Device Market Key Players and Competitive Insights**

The Oncology Device Market is a dynamic and rapidly evolving industry that plays a crucial role in the diagnosis, treatment, and management of cancer. As the global burden of cancer continues to rise, the demand for advanced oncology devices is also experiencing significant growth.

This market is characterized by intense competition among various players, each striving to enhance their product offerings and technological capabilities. Key components driving the market include the increasing prevalence of cancer, advancements in medical technology, and a growing emphasis on early diagnosis and personalized treatment approaches.

Companies are increasingly focusing on innovation, strategic collaborations, mergers and acquisitions, and the expansion of their geographical footprints to gain a competitive edge in a landscape marked by regulatory challenges and market entry barriers.

Siemens Healthineers has established a formidable presence in the Oncology Device Market through its commitment to providing cutting-edge medical technologies. This company has developed a range of advanced imaging systems and diagnostic tools that are essential for effective cancer detection and monitoring.

Siemens Healthineers is known for its strengths in integrating artificial intelligence with imaging technologies, which enhances diagnostic accuracy and promotes better patient outcomes. Furthermore, Siemens Healthineers invests significantly in research and development, ensuring that it remains at the forefront of innovation in oncology devices.

The company's extensive global network and established partnerships with healthcare providers further bolster its market presence, enabling it to deliver tailored solutions that meet diverse healthcare needs across different regions.

GE Healthcare has made significant contributions to the Oncology Device Market, specializing in a variety of imaging and diagnostic devices used in oncology settings. The company is recognized for its advanced technology that supports clinicians in making informed decisions regarding cancer diagnosis and treatment.

GE Healthcare's strength lies in its comprehensive product portfolio, which includes high-performance MRI, CT, and molecular imaging systems designed to provide superior visualization of tumors and other concerning structures in the body.

Additionally, the company emphasizes the integration of digital health technologies to enhance patient care, streamline workflows, and facilitate real-time data analysis, which is vital for effective cancer management.

GE Healthcare's global presence and commitment to innovation position it as a leading player in the oncology device landscape, addressing the growing demand for efficient and effective healthcare solutions in oncology.

### **Key Companies in the oncology device market include**

- [Siemens Healthineers](https://www.siemens-healthineers.com/en-in/clinical-specialities/oncology/interventional-oncology-procedures)
- GE Healthcare
- Varian Medical Systems
- Accuray
- Boston Scientific
- CRAD
- Medtronic
- Bayer
- Hologic
- Thermo Fisher Scientific
- Philips
- Elekta
- NantHealth
- Toshiba Medical Systems

## Oncology Device Market Industry Developments

- **Q2 2024: Varian Receives FDA Clearance for TrueBeam and Edge Radiotherapy Systems with HyperSight Imaging** Varian, a Siemens Healthineers company, announced it received FDA 510(k) clearance for its TrueBeam and Edge radiotherapy systems equipped with HyperSight imaging, enhancing image-guided cancer treatment capabilities.
- **Q2 2024: RefleXion Announces FDA Clearance for SCINTIX Biology-Guided Radiotherapy for Lung and Bone Cancers** RefleXion Medical received FDA clearance for its SCINTIX biology-guided radiotherapy to treat lung and bone cancers, expanding the clinical indications for its novel oncology device.
- **Q2 2024: OncoRes Medical Raises $17.5 Million in Series B Funding to Advance Intraoperative Imaging Device** OncoRes Medical secured $17.5 million in Series B funding to accelerate the development and commercialization of its intraoperative imaging device for cancer surgery.
- **Q2 2024: Accuray Announces CE Mark for Radixact System with Synchrony for Real-Time Motion Synchronization** Accuray received CE Mark approval for its Radixact System with Synchrony, enabling real-time motion synchronization during radiotherapy for cancer patients in Europe.
- **Q2 2024: Theragenics Corporation Acquires C4 Imaging to Expand Brachytherapy Portfolio** Theragenics Corporation announced the acquisition of C4 Imaging, a developer of MRI markers for brachytherapy, to strengthen its position in the oncology device market.
- **Q3 2024: ViewRay Announces Partnership with Elekta to Integrate MRIdian MRI-Guided Radiation Therapy with Elekta’s Oncology Solutions** ViewRay and Elekta entered a strategic partnership to integrate ViewRay’s MRIdian MRI-guided radiation therapy system with Elekta’s oncology workflow solutions.
- **Q3 2024: XACT Robotics Receives FDA Clearance for XACT ACE Robotic System for Percutaneous Procedures in Oncology** XACT Robotics received FDA clearance for its XACT ACE Robotic System, enabling precise percutaneous procedures for oncology applications.
- **Q3 2024: Boston Scientific Announces FDA Approval of TheraSphere Y-90 Glass Microspheres for Colorectal Cancer Liver Metastases** Boston Scientific received FDA approval for its TheraSphere Y-90 Glass Microspheres for the treatment of colorectal cancer liver metastases, expanding its interventional oncology portfolio.
- **Q4 2024: Nano-X Imaging Ltd. Announces FDA Clearance for Nanox.ARC Multi-Source Digital X-ray Device for Oncology Applications** Nano-X Imaging Ltd. received FDA clearance for its Nanox.ARC multi-source digital X-ray device, which is designed to improve imaging for oncology diagnostics.
- **Q4 2024: Elekta Opens New Global Innovation Center for Radiation Therapy in Stockholm** Elekta inaugurated a new global innovation center in Stockholm dedicated to advancing radiation therapy technologies for cancer treatment.
- **Q1 2025: CureMetrix Raises $30 Million Series C to Accelerate AI-Powered Oncology Imaging Solutions** CureMetrix closed a $30 million Series C funding round to expand its AI-powered imaging solutions for oncology diagnostics and workflow optimization.
- **Q2 2025: Medtronic Announces FDA Approval of Hugo™ Robotic-Assisted Surgery System for Urologic Oncology Procedures** Medtronic received FDA approval for its Hugo™ robotic-assisted surgery system, enabling its use in urologic oncology procedures in the United States.

### **Oncology Device Market Segmentation Insights**

### **Oncology Device Market Application Outlook**

- Radiation Therapy
- Chemotherapy
- Surgical Oncology
- Supportive Care
- Diagnostic Imaging

### **Oncology Device Market Device Type Outlook**

- Radiotherapy Equipment
- Chemotherapy Administration Devices
- Surgical Instruments
- Diagnostic Imaging Devices
- Supportive Devices

### **Oncology Device Market End User Outlook**

- Hospitals
- Ambulatory Surgical Centers
- Specialized Oncology Clinics
- Home Care Settings

### **Oncology Device Market Technology Outlook**

- Photodynamic Therapy
- Radiotherapy
- Cryoablation
- Electrochemotherapy

### **Oncology Device Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### Increasing Cancer Incidence

由于全球癌症发病率不断上升，肿瘤设备市场正在经历增长。根据最近的统计数据，癌症病例预计将大幅增加，预计到 2040 年，每年新增癌症病例数可能达到 2950 万例。这种令人震惊的趋势需要开发和部署先进的肿瘤设备，以促进早期检测、诊断和治疗。
 
随着医疗保健系统努力应对这一日益增长的负担，对创新肿瘤设备的投资可能会激增，从而推动市场扩张。此外，人们对癌症筛查和预防措施的认识不断提高，促进了对复杂肿瘤设备的需求，从而改善了整体市场格局。
 

- IHME 数据将癌症列为全球疾病负担的主要原因之一，每年诊断出数百万新病例。老龄化人口和发展中经济体的发病率不断上升，继续扩大对先进肿瘤诊断、成像系统和治疗技术的需求。

### Advancements in Treatment Technologies

治疗技术的不断进步推动了肿瘤设备市场的发展。靶向治疗、免疫疗法和个性化医疗等创新正在重塑癌症患者的治疗格局。这些先进治疗方式与肿瘤设备的整合提高了其疗效和精确度。例如，下一代测序技术的发展彻底改变了肿瘤学家进行癌症治疗的方式，允许根据个体基因图谱进行定制治疗。
 
随着医疗保健提供者寻求优化患者的治疗效果，这种向个性化治疗的转变预计将推动对先进肿瘤设备的需求。因此，在对支持这些尖端治疗方法的设备的需求的推动下，肿瘤设备市场可能会出现大幅增长。
 

- PubMed 研究表明，靶向治疗、图像引导干预和个性化治疗方法可显着提高治疗精度和患者预后。肿瘤学技术的持续创新增加了对支持诊断、监测和治疗的先进设备的需求。

### Regulatory Support for Innovative Devices

肿瘤设备市场正在经历有利的监管支持，这对于引进创新肿瘤设备至关重要。监管机构越来越简化新设备的审批流程，从而鼓励制造商投资于研发。
 
这种支持性环境有利于尖端技术的快速引入，从而显着改善癌症的诊断和治疗。例如，突破性设备的快速审批途径使患者能够更快地获得救生技术。随着监管框架的不断发展，在满足医疗保健提供者和患者不断增长的需求的创新设备的涌入的推动下，肿瘤设备市场预计将扩大。
 

- 世界银行医疗保健指标显示，全球对医疗保健创新和医疗技术基础设施的投资不断增加。支持性监管框架和医疗保健现代化举措正在帮助加快先进肿瘤设备在发达和新兴医疗保健市场的采用。

### Rising Demand for Home Healthcare Solutions

在以患者为中心的护理需求不断增长的推动下，肿瘤设备市场正在向家庭医疗保健解决方案转变。患者越来越多地寻求能够让他们在舒适的家中管理自己健康的选择，特别是在癌症治疗的背景下。这一趋势促使制造商开发适合家庭使用的肿瘤设备，例如便携式诊断工具和远程监控系统。
 
这些设备的便利性和可访问性对患者和医疗保健提供者都有吸引力，因为它们有助于持续护理和监测，而无需频繁去医院。因此，随着更多创新的家庭医疗保健解决方案的推出，满足患者不断变化的偏好，肿瘤设备市场可能会增长。
 

- PubMed 研究强调癌症患者越来越多地采用远程患者监测和家庭医疗保健解决方案。这些技术提高了治疗依从性，实现持续监测，并减少不必要的医院就诊，满足了对家庭兼容肿瘤设备不断增长的需求。

### Growing Investment in Healthcare Infrastructure

肿瘤设备市场受益于各地区医疗基础设施投资的增加。政府和私营实体正在认识到加强医疗设施以应对日益增加的癌症负担的重要性。这项投资旨在升级医疗设备，包括肿瘤设备，以确保医疗保健提供者能够提供高质量的护理。
 
例如，专门的癌症治疗中心的建立正在增加，这需要采购先进的肿瘤设备。此外，肿瘤学研究和开发的资金不断增加，从而引入了提高诊断和治疗能力的创新设备。这一趋势可能会提振肿瘤设备市场，因为增强的基础设施支持先进技术的采用。
 

- 世界银行数据显示多个地区的医疗保健支出持续增长。增加对癌症中心、诊断设施和先进治疗基础设施的资助正在改善获得肿瘤服务的机会，并支持更多地部署创新肿瘤设备。

## Future Outlook

肿瘤设备市场预计将在2024年至2035年间以6.18%的年均增长率增长，推动因素包括技术进步、癌症发病率上升和医疗支出增加。

**New opportunities:**

- 基于人工智能的诊断影像设备开发

到2035年，肿瘤设备市场预计将实现显著增长和创新。

## Segment Insights

### 按应用：放射治疗（最大）与化疗（增长最快）

在肿瘤设备市场中，放射治疗成为最大的细分市场，因其在治疗各种类型癌症方面的有效性而被广泛采用。由于其成熟的技术和治疗方案的整合，它占据了 36% 的份额。紧随其后的是化疗，这是癌症治疗的重要组成部分，越来越多地与靶向治疗一起使用，扩大了其市场份额。市场份额的整体分布呈现出竞争格局，肿瘤外科、支持护理和诊断影像也占据着重要地位，因为它们迎合了癌症患者的整体治疗。

波士顿科学公司继续通过创新干预技术和合作研究计划支持肿瘤治疗的进步。到 2024 年，放射治疗约占肿瘤设备市场的 36%，反映了其在癌症治疗方案中的既定作用以及多种肿瘤类型的广泛临床采用。

### 按设备类型：放射治疗设备（最大）与化疗管理设备（增长最快）

肿瘤设备市场展示了有助于癌症治疗效率的各种设备类型。其中，放射治疗设备占据最大的市场份额，达到39%，这主要是由于先进技术的不断采用以及患者对有效癌症治疗的需求。相比之下，化疗给药设备正在迅速获得关注，反映出治疗方案中向更高效的药物输送系统和自动化解决方案的转变。

西门子 Healthineers 通过持续创新不断增强放射治疗规划和成像技术。到 2024 年，放射治疗设备约占设备类型细分市场的 39%，这得益于精密放射技术的利用率不断提高以及对先进癌症治疗基础设施不断增长的需求。

### 按最终用户：医院（最大）与专业肿瘤诊所（增长最快）

在肿瘤设备市场中，终端用户的市场份额分布显示医院占据主导地位，医院为61%的肿瘤患者提供全面的治疗服务和先进技术。门诊手术中心和专门的肿瘤诊所也对这一领域做出了贡献，尽管程度较小。家庭护理机构逐渐兴起，提供了便利，但与大型机构相比仍然落后。该细分市场的增长趋势凸显了向专业治疗设施的转变，其中专业肿瘤诊所的增长率最快。这一趋势是由对个性化医疗的日益关注和对先进癌症疗法的需求推动的。此外，分散护理的发展增强了家庭护理环境的作用，导致患者管理方法多样化。

医院（主要）与专科肿瘤诊所（新兴）

医院因其丰富的资源、多学科团队以及提供全面癌症护理的能力而成为肿瘤设备市场中占主导地位的最终用户群体。它们配备了先进的成像和治疗技术，使其成为复杂肿瘤病例的首选。相反，在对专门护理、以患者为中心的方法以及专门针对癌症治疗的简化服务的需求不断增长的推动下，专门的肿瘤诊所正在迅速兴起。这些诊所通常提供靶向治疗和临床试验，吸引寻求尖端治疗方案的患者。虽然医院仍然很普遍，但专科诊所正在开辟一个重要的利基市场，提供越来越受到患者追捧的替代方案。

### 按技术分类：放射疗法（最大）与电化学疗法（增长最快）

在肿瘤设备市场中，放射治疗仍然是最大的细分市场，由于其在治疗各种癌症方面的既定功效，占据了 42% 的份额。它在医疗机构中被广泛采用，并得到大量临床数据的支持。继放射治疗之后，光动力治疗和冷冻消融占据了显着份额，提供了有效的靶向治疗选择。电化学疗法虽然所占份额较小，但因其创新方法而受到关注。由于这些技术的治疗优势和以患者为中心的好处，市场正在见证向这些技术的转变。

技术：放射疗法（主导）与电化学疗法（新兴）

放射治疗是肿瘤设备市场的主导技术，利用先进的成像和治疗技术精确瞄准肿瘤，同时最大限度地减少对周围组织的损害。其在临床环境中的广泛应用，加上立体定向身体放射治疗等不断取得的进步，巩固了其市场领导地位。相比之下，电化学疗法正在成为一种有前途的治疗方式，利用化疗和电脉冲的协同作用来增强肿瘤细胞内的药物输送。这种创新方法对于难以接近的肿瘤患者特别有吸引力，并且正在越来越多地融入临床实践，标志着向微创癌症治疗方法的转变。

## Regional Market Share Analysis

### 北美：引领创新和需求

北美在肿瘤设备市场处于领先地位，到 2024 年将占全球收入的 45.04% 以上。该地区的增长是由先进的医疗基础设施、不断增加的癌症患病率以及对研发的大量投资推动的。 FDA 等机构的监管支持进一步促进创新，确保新技术的快速批准。

- 疾病预防控制中心的统计数据表明，癌症仍然是美国的主要原因之一，有数百万人被诊断患有癌症。扩大筛查计划、增加早期检测工作以及不断采用先进肿瘤技术，继续支持北美地区对肿瘤设备的强劲需求。

对微创手术的需求 [个性化医疗](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937)也呈上升趋势，有助于市场扩张。美国是该市场的主要贡献者，美敦力 (Medtronic)、波士顿科学 (Boston Scientific) 和雅培实验室 (Abbott Laboratories) 等主要参与者处于领先地位。竞争格局的特点是大公司之间的持续创新和战略伙伴关系。加拿大也发挥着重要作用，重点关注加强医疗保健服务和改善患者治疗效果。老牌企业和新兴初创企业的存在营造了一个充满活力的增长环境。

- GE Healthcare 继续投资人工智能成像系统、精准诊断和以肿瘤学为中心的解决方案，以改善癌症检测和治疗规划。持续的技术进步正在帮助医疗保健提供者提供更加个性化的护理，同时加强整个北美的肿瘤学基础设施。

### 欧洲：监管支持和增长

2024年欧洲肿瘤器械市场价值为236.46亿美元，成为第二大区域市场，占有30%的份额。 该地区受益于强大的医疗保健系统和不断增长的人口老龄化，这推动了对癌症治疗技术的需求。医疗器械法规 (MDR) 等监管框架可确保高安全性和有效性标准，从而增强消费者信心和市场增长。

- 欧洲药品管理局 (EMA) 继续通过严格的监管途径支持创新，以促进先进的癌症技术和疗法的获得。对患者安全、治疗功效和加速创新的高度重视有助于推动现代肿瘤设备在欧洲主要医疗保健市场的采用。

此外，增加对医疗保健技术和研究的投资预计将进一步推动市场发展。德国、法国和英国是该市场的领先国家，其中西门子医疗和飞利浦等公司做出了重大贡献。竞争格局以成熟企业和创新型初创企业的混合为特征，重点关注肿瘤学领域的人工智能和机器人技术等先进技术。公共和私营部门之间的合作正在增强研究能力并加速产品开发，使欧洲成为肿瘤设备市场的关键参与者。

### 亚太地区：快速增长和潜力

亚太地区的肿瘤器械市场正在快速增长，约占全球份额的 20%。癌症发病率上升、医疗保健支出增加以及对先进医疗技术的日益关注推动了该地区的扩张。中国和印度等国家正在大力投资医疗基础设施，预计这将增加获得肿瘤设备的机会。监管机构也在简化审批流程，以鼓励创新和市场进入。中国是该地区最大的市场，其次是日本和印度，本地和国际参与者都有强大的影响力。

GE医疗集团和瓦里安医疗系统公司等公司正在积极扩大在该地区的业务。竞争格局的特点是老牌公司和新兴初创公司混合存在，重点关注负担得起且有效的肿瘤学解决方案。政府和私营部门之间日益加强的合作预计将进一步推动市场增长。

### 中东和非洲：充满挑战的新兴市场

中东和非洲地区在肿瘤器械市场中逐渐崛起，占据全球约5%的份额。这一增长的推动因素包括癌症意识的提高、医疗基础设施的改善以及医疗技术投资的增加。然而，经济差距和监管障碍等挑战仍然存在。南非和阿联酋等国家正在引领市场，努力改善癌症患者的医疗保健机会和治疗选择。

南非是该地区最大的市场，得到越来越多的医疗设施和旨在改善癌症护理的举措的支持。竞争格局包括本地制造商和寻求扩大业务的国际公司。主要参与者专注于建立伙伴关系和合作，以应对该地区的独特挑战，旨在提供创新且具有成本效益的肿瘤学解决方案。

## Competitive Benchmarking

肿瘤设备市场目前的特点是动态竞争格局，其驱动因素包括技术进步、癌症患病率的增加以及对个性化医疗的日益重视。美敦力（Medtronic）（美国）、西门子医疗（德国）和瓦里安医疗系统（美国）等主要参与者都进行了战略定位，利用创新和合作伙伴关系来增强其市场占有率。美敦力（美国）专注于将数字健康解决方案集成到其肿瘤设备中，而西门子医疗（德国）则强调先进的成像技术以提高诊断准确性。瓦里安医疗系统（美国）致力于开发尖端的放射治疗解决方案，这些解决方案共同塑造了一个优先考虑技术优势和以患者为中心的方法的竞争环境。肿瘤设备市场的关键业务策略包括本地化制造和优化供应链以提高运营效率。市场结构显得较为分散，几个主要参与者发挥着重大影响力。这种碎片化允许提供多样化的产品和服务，从而促进竞争，推动创新。这些公司的集体战略不仅增强了各自的市场地位，而且有助于形成鼓励持续改进和适应的强大竞争框架。
 
2025 年 8 月，美敦力（美国）宣布与一家领先的远程医疗提供商建立战略合作伙伴关系，以增强肿瘤患者的远程患者监测能力。此次合作意义重大，因为它符合数字健康解决方案的不断增长趋势，能够更好地患者参与并有可能改善治疗结果。通过将远程医疗整合到其肿瘤设备产品中，美敦力（美国）将自己置于快速发展的医疗保健领域的前沿。 
 
2025 年 9 月，西门子 Healthineers (DE) 推出了全新的人工智能驱动成像平台，旨在简化肿瘤科医生的诊断流程。这项创新至关重要，因为它不仅提高了癌症检测的准确性，还减少了诊断所需的时间，从而改善了患者护理。西门子 Healthineers (DE) 似乎正在利用医疗保健领域对人工智能集成不断增长的需求，这可能会在肿瘤设备市场提供竞争优势。
 
2025 年 7 月，瓦里安医疗系统（美国）通过在亚洲建立新的制造工厂扩大了其全球足迹，旨在提高其先进放射治疗系统的生产能力。此举表明瓦里安致力于满足新兴市场对肿瘤设备不断增长的需求。通过本地化生产，瓦里安（美国）不仅降低了供应链的复杂性，还增强了快速响应区域市场需求的能力。
 
截至 2025 年 10 月，肿瘤设备市场当前的竞争趋势在很大程度上受到数字化、可持续性和人工智能集成的影响。主要参与者之间的战略联盟正在塑造格局，促进创新和协作。从基于价格的竞争向关注技术进步和供应链可靠性的转变是显而易见的，这表明未来的竞争差异将取决于创新和提供高质量、可靠的肿瘤学解决方案的能力。

## Recent News & Developments

- **2024年第二季度：Varian获得FDA对TrueBeam和Edge放射治疗系统及HyperSight成像的批准** Varian，一家西门子医疗公司，宣布其TrueBeam和Edge放射治疗系统获得FDA 510(k)批准，配备HyperSight成像，增强了图像引导的癌症治疗能力。
- **2024年第二季度：RefleXion宣布SCINTIX生物引导放射治疗获得FDA批准，用于肺癌和骨癌** RefleXion Medical获得FDA批准，其SCINTIX生物引导放射治疗用于治疗肺癌和骨癌，扩展了其新型肿瘤设备的临床适应症。
- **2024年第二季度：OncoRes Medical获得1750万美元B轮融资，以推进术中成像设备的开发** OncoRes Medical获得1750万美元B轮融资，以加速其用于癌症手术的术中成像设备的开发和商业化。
- **2024年第二季度：Accuray宣布Radixact系统与Synchrony的CE标记，用于实时运动同步** Accuray获得其Radixact系统与Synchrony的CE标记批准，使其在欧洲的癌症患者放射治疗中实现实时运动同步。
- **2024年第二季度：Theragenics Corporation收购C4 Imaging以扩展其近距离放射治疗产品组合** Theragenics Corporation宣布收购C4 Imaging，一家MRI标记物开发公司，以增强其在肿瘤设备市场的地位。
- **2024年第三季度：ViewRay宣布与Elekta合作，将MRIdian MRI引导放射治疗与Elekta的肿瘤解决方案整合** ViewRay与Elekta达成战略合作，将ViewRay的MRIdian MRI引导放射治疗系统与Elekta的肿瘤工作流解决方案整合。
- **2024年第三季度：XACT Robotics获得FDA批准，推出XACT ACE机器人系统，用于肿瘤学的经皮手术** XACT Robotics获得FDA批准，其XACT ACE机器人系统，使其能够进行精确的经皮手术，应用于肿瘤学。
- **2024年第三季度：波士顿科学宣布TheraSphere Y-90玻璃微球用于结直肠癌肝转移的FDA批准** 波士顿科学获得FDA批准，其TheraSphere Y-90玻璃微球用于治疗结直肠癌肝转移，扩展其介入肿瘤学产品组合。
- **2024年第四季度：Nano-X Imaging Ltd.宣布Nanox.ARC多源数字X射线设备获得FDA批准，用于肿瘤学应用** Nano-X Imaging Ltd.获得FDA批准，其Nanox.ARC多源数字X射线设备，旨在改善肿瘤学诊断的成像。
- **2024年第四季度：Elekta在斯德哥尔摩开设新的全球放射治疗创新中心** Elekta在斯德哥尔摩揭幕新的全球放射治疗创新中心，致力于推进癌症治疗的放射治疗技术。
- **2025年第一季度：CureMetrix获得3000万美元C轮融资，以加速AI驱动的肿瘤成像解决方案** CureMetrix完成3000万美元C轮融资，以扩展其AI驱动的肿瘤学诊断和工作流优化成像解决方案。
- **2025年第二季度：美敦力宣布Hugo™机器人辅助手术系统获得FDA批准，用于泌尿肿瘤手术** 美敦力获得FDA批准，其Hugo™机器人辅助手术系统，允许在美国用于泌尿肿瘤手术。

## Report Scope

| 2024年市场规模 | 78.82（十亿美元） |
| --- | --- |
| 2025年市场规模 | 83.69（十亿美元） |
| 2035年市场规模 | 152.48（十亿美元） |
| 年复合增长率（CAGR） | 6.18%（2024 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 十亿美元 |
| 主要公司简介 | 市场分析进行中 |
| 覆盖的细分市场 | 市场细分分析进行中 |
| 主要市场机会 | 人工智能在诊断成像中的整合提高了肿瘤设备市场的精确度。 |
| 主要市场动态 | 技术进步和监管变化推动肿瘤设备市场的创新和竞争。 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 到2035年，肿瘤设备市场的预计市场估值是多少？**
A: 到2035年，肿瘤设备市场预计将达到1524.8亿美元的估值。

**Q: 2024年肿瘤设备市场的市场估值是多少？**
A: 2024年，肿瘤设备市场的价值为788.2亿美元。

**Q: 在2025年至2035年的预测期内，肿瘤设备市场的预期CAGR是多少？**
A: 在2025年至2035年的预测期内，肿瘤设备市场的预期CAGR为6.18%。

**Q: 2024年肿瘤设备市场哪个细分领域的估值最高？**
A: 在2024年，化疗部门的估值最高，达200亿美元。

**Q: 肿瘤设备市场的关键参与者有哪些？**
A: 肿瘤设备市场的主要参与者包括美敦力、波士顿科学、雅培实验室、西门子医疗和飞利浦。

**Q: 到2035年，放射治疗部门的预计估值是多少？**
A: 放射治疗部门预计到2035年将达到300亿美元的估值。

**Q: 2024年，外科肿瘤学部门的估值与支持性护理部门相比如何？**
A: 在2024年，外科肿瘤学部门的估值为180亿美元，而支持性护理部门的估值为120.6亿美元。

**Q: 2024年至2035年，诊断影像设备的预期增长是多少？**
A: 诊断影像设备部门预计将从2024年的200亿美元增长到2035年的400亿美元。

**Q: 到2035年，预计哪个最终用户细分市场的估值最高？**
A: 到2035年，医院部门预计将拥有最高的估值，达到610亿美元。

**Q: 2024年至2035年化疗给药设备的预计增长是多少？**
A: 化疗给药设备预计将从2024年的150亿美元增长到2035年的300亿美元。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/oncology-device-market-34121*